Erik Anders Kronström

Director de Operaciones en INFANT BACTERIAL THERAPEUTICS AB .

Fortuna: 106 222 $ al 31/05/2024

57 años

Health Technology

Consumer Services

Perfil

Erik Anders Kronström is currently the Chief Operating Officer at Infant Bacterial Therapeutics AB since 2018.
Previously, he worked as the Chief Executive Officer at Biosergen AS.
He holds an MBA from Warwick Business School and a graduate degree from the Royal Institute of Technology.

Participaciones conocidas en empresas públicas

Empresa	Fecha	Número de acciones	Valoración	Fecha de valoración
INFANT BACTERIAL THERAPEUTICS AB CLASS B 0.09%	28/05/2024	11 194 ( 0.09% )	106 222 $	31/05/2024

Cargos activos de Erik Anders Kronström

Empresas	Cargo	Inicio
INFANT BACTERIAL THERAPEUTICS AB	Director de Operaciones	01/01/2018

Todos los cargos activos de Erik Anders Kronström

Antiguos cargos conocidos de Erik Anders Kronström.

Empresas	Cargo	Fin
Biosergen AS Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.	Director Ejecutivo	-

Ver el detalle de la experiencia de Erik Anders Kronström.

Formación de Erik Anders Kronström.

Royal Institute of Technology	Graduate Degree
Warwick Business School	Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Erik Anders Kronström.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
INFANT BACTERIAL THERAPEUTICS AB	Health Technology

Empresas privadas	1
Biosergen AS Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.	Health Technology